MedTrace Logo

Gut Microbiota and Glioblastoma Multiforme Prognosis

NCT03631823 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-08-15

No results posted yet for this study

Summary

Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. Conventional therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with temozolomide), have not resulted in major improvements in the survival outcomes with only a median survival of around 15 months.The main reason may be related to the highly immunosuppressive tumor microenvironment. In recent years, the microbiome has emerged as a key regulator of not only systemic immune regulation but brain circuitry, neuro-physiology and microglia development. We hypothesized that there is a link between the gut microbiota and the GBM development and evolution through the immune regulation cells (microglia and tumor related macrophagocyte) in the blood circulation to impact the prognosis( PFS and MST) of GBM patients.

Conditions

  • Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis

Interventions

OTHER

Chemotherapy with temozolomide or no chemotherapy

This study is just an observational study.

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Jinsong Wu, Ph.D. & M.D · Huashan Hospital

  • Weifeng Shi, Ph.D. · Taishan Medical Univiersity

  • Yingchao Liu, Ph.D. & M.D · Shandong provincial hospirtal affiliated to Shandong University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2019-08-10
Completion
2020-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03631823 on ClinicalTrials.gov